- |||||||||| TG4010 / Transgene, Stimuvax (tecemotide) / EMD Serono, Seattle Genetics, Lucanix (belagenpumatucel-L) / Activate Immunotherapy
Retrospective data, Review, Journal, IO Complimentary Diagnostic: Efficacy and safety of antigen-specific immunotherapy in the treatment of patients with non-small-cell lung cancer: a systematic review and meta-analysis. (Pubmed Central) - Jul 10, 2020
However, these evidences might be limited by potential biases. Therefore, further well-conducted, large-scale RCTs are needed to verify our findings.
- |||||||||| Lucanix (belagenpumatucel-L) / Activate Immunotherapy
Trial completion, Trial primary completion date, Metastases: STOP: Phase III Lucanix (clinicaltrials.gov) - May 8, 2015
P3, N=532, Completed,
Therefore, further well-conducted, large-scale RCTs are needed to verify our findings. Active, not recruiting --> Completed | Trial primary completion date: Jun 2012 --> Jan 2013
- |||||||||| Lucanix (belagenpumatucel-L) / Activate Immunotherapy
Enrollment closed, Metastases: STOP: Phase III Lucanix (clinicaltrials.gov) - May 28, 2012
P3, N=506, Active, not recruiting,
Active, not recruiting --> Completed | Trial primary completion date: Jun 2012 --> Jan 2013 Recruiting --> Active, not recruiting
|
